Basel Medical Group Ltd Kicks Off US$ 1.0 Billion Bitcoin (BTC) Acquisition Strategy Move

Singapore, May 15, 2025 - Basel Medical Group Ltd ("BMGL" or the
"Company") (Nasdaq: BMGL) today announced the Company has entered exclusive negotiations for a US$1 billion bitcoin acquisition that will diversify its treasury reserves to a very large extent, while maintaining its core focus on medical services expansion. This is a major strategic financial initiative to strengthen its balance sheet and support its aggressive expansion across Asia's high-growth healthcare markets.

Strategic Financial Restructuring for Growth
BMGL is in advanced discussions with a consortium of institutional investors and high-net-worth individuals, who are influential in the crypto space, to acquire a US$1 billion Bitcoin (BTC), through an innovative share-swap arrangement. This landmark transaction represents one of the largest corporate balance sheet enhancements in the Asia-Pacific healthcare sector.

Strengthening the Foundation for Regional Expansion
The proposed US$1 billion capital infusion will:
- Create one of the strongest balance sheets among Asia-focused healthcare providers
- Provide unmatched financial flexibility for mergers and acquisitions
- Establish a diversified asset base to weather market volatility
- Position BMGL as the best-capitalized medical group in emerging Asian markets

Management Commentary
Dr Darren Chhoa, Group Chief Executive Officer of BMGL, emphasized: "This US$1 billion financial transformation will give us unprecedented capacity to execute our Asia growth strategy while maintaining conservative financial management. Our expanded balance sheet will allow us to move quickly on strategic opportunities as we build the modern accessible tech enhanced healthcare platform across high-growth Asian markets." This financial strategy positions BMGL to capitalize on Asia's booming healthcare demand while maintaining a fortified balance sheet. The Company expects to finalize terms within the current quarter, subject to standard closing conditions and regulatory approvals.